Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Pharmacogenomics Journal

• Publication date

  2014-06-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/tpj.2014.24PMID 24958282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

  2014cited by this paper
• MDM2, MDMX and p53 in oncogenesis and cancer therapy

  2013cited by this paper
• Genetic polymorphisms in catalase and CYP1B1 determine DNA adduct formation by benzo(a)pyrene ex vivo.

  2013cited by this paper
• Abstract 2200: Relationship between cytochrome P450 1B1 (CYP1B1) and head and neck cancer cells proliferation, dissemination and chemosensitivity to anticancer drugs.

  2013cited by this paper
• Role of CYP1B1 gene polymorphisms in bladder cancer susceptibility.

  2012cited by this paper
• Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation.

  2012cited by this paper
• Lack of association of ADH1C genotype with breast cancer susceptibility in Caucasian population: a pooled analysis of case-control studies.

  2012cited by this paper
• Cancer pharmacogenomics: strategies and challenges

  2012cited by this paper
• Abstract 1872: Identification of novel single-nucleotide polymorphisms associated with anticancer drug effects using the SNPChip384 platform

  2012cited by this paper
• TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

  2011cited by this paper
• Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk.

  2011cited by this paper
• Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models

  2010cited by this paper
• The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects.

  2010cited by this paper
• The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models

  2009cited by this paper
• Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene

  2009cited by this paper
• CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians

  2008cited by this paper
• A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans

  2007cited by this paper
• MDM2 Promoter Polymorphism SNP309 Contributes to Tumor Susceptibility: Evidence from 21 Case-Control Studies

  2007cited by this paper
• Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel.

  2006cited by this paper
• Risk factors in alcohol associated breast cancer: alcohol dehydrogenase polymorphism and estrogens.

  2004cited by this paper
• THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY

  2001cited by this paper
• A simple p53 functional assay for screening cell lines, blood, and tumors.

  1995cited by this paper
• The gamma 1 and gamma 2 subunits of human liver alcohol dehydrogenase. cDNA structures, two amino acid replacements, and compatibility with changes in the enzymatic properties.

  1986cited by this paper
• A Simple Sequentially Rejective Multiple Test Procedure

  1979cited by this paper

• Amino Acid Stress Response Genes Contribute to a 25‐Fold Increased Risk of L‐Asparaginase–Induced Hypersensitivity

  2025cites this paper
• Potential role of genetic polymorphisms in neoadjuvant chemotherapy response in breast cancer

  2024cites this paper
• Thai pharmacogenomics database −2 (TPGxD‐2) sequel to TPGxD‐1, analyzing genetic variants in 26 non‐VIPGx genes within the Thai population

  2024cites this paper
• CPMKG: a condition-based knowledge graph for precision medicine

  2024cites this paper
• Novel insights into the pathogenesis of thyroid eye disease through ferroptosis-related gene signature and immune infiltration analysis

  2024cites this paper
• Genetic variant of ADH1C for predicting survival in esophageal squamous cell cancer patients who underwent postoperative radiotherapy

  2022cites this paper
• Breast cancer pharmacogenetics: a systematic review.

  2022cites this paper
• MDM4: What do we know about the association between its polymorphisms and cancer?

  2022cites this paper
• Single nucleotide polymorphisms as the efficient prognostic markers in breast cancer.

  2021cites this paper
• Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma

  2020cites this paper
• Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma

  2020cites this paper
• Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450

  2020cites this paper
• A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer

  2018cites this paper
• SurvivalGWAS_SV: software for the analysis of genome-wide association studies of imputed genotypes with “time-to-event” outcomes

  2017cites this paper
• MDM2 344T>A polymorphism; could it be a predictive marker of anthracycline resistance?

  2016cites this paper
• On the use of pharmacogenetics in cancer treatment and clinical trials.

  2014cites this paper
• Drug development review An overview of recent publications featuring Illumina technology

  year unknowncites this paper